Third-generation aromatase inhibitors (AIs) have become the cornerstone of endocrine therapy for postmenopausal HR+ ​patients with breast cancer,2 demonstrating proven efficacy in suppressing estrogen production and reducing recurrence risk.3 The gene discussed is CYP19A1; the disease is breast cancer.